Conduit Pharmaceuticals Inc. has reported a significant change in ownership to the SEC, as detailed in a Form 3 filing dated August 6, 2024. The filing indicates that Nirland Ltd has acquired 12,500,000 shares of common stock and holds warrants for an additional 2,000,000 shares. The shares were issued in connection with a Senior Secured Promissory Note related to a business combination. Nirland Ltd is part of a group of entities including Stockton Ltd, The Rowland Master Trust, and Dovet Ltd, which collectively may be deemed to share beneficial ownership of the securities. The filing was signed by directors David Rowland and Barclay Rowland on behalf of the respective entities on August 13, 2024.

Conduit Pharmaceuticals Inc. has reported a significant change in ownership to the SEC, as detailed in a Form 3 filing dated August 6, 2024. The filing indicates that Nirland Ltd has acquired 12,500,000 shares of common stock and holds warrants for an additional 2,000,000 shares. The shares were issued in connection with a Senior Secured Promissory Note related to a business combination. Nirland Ltd is part of a group of entities including Stockton Ltd, The Rowland Master Trust, and Dovet Ltd, which collectively may be deemed to share beneficial ownership of the securities. The filing was signed by directors David Rowland and Barclay Rowland on behalf of the respective entities on August 13, 2024.